Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.
BACKGROUND
In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily doses with no up-titration, whereas DMF treatment is recommended twice-daily (BID) and is initiated with a 7-day starter dose of 120 mg BID before up-titration to the maintenance dose of 240 mg BID. Limited information exists regarding real-world ODMT prescribing patterns to aid physician/patient decision-making.


METHODS
Eligible patients for this retrospective medical record review were ≥18 years, had one visit related to ODMT initiation (index visit), and ≥1 visit within 12 months before and after the index visit. Primary objectives were to assess post-index ODMT persistency (i.e., discontinuation), prescribing patterns (medication switching, dose up-titrations, dose reduction, re-starts, and add-ons) and medical resource utilization (office-visits, MRI procedures, and mobility indicators) at distinct time windows of 3, 6, 9, and 12 months. Chi-square or Wilcoxon Rank Sum tests were used for 3-way ODMT group comparisons.


RESULTS
Medical records of 293 MS-diagnosed patients using ODMTs were abstracted from 19 US-based neurology clinics between December 31, 2010 and June 30, 2014 (FTY: 101; DMF: 133; TFN: 59). Persistency rates among ODMT groups were similar. MS-related medication switching, dose reduction, re-starts, and add-ons were infrequently observed and were similar across ODMT groups. Of DMF patients with a confirmed starting dose of 120 mg BID with ≥12 months follow-up (n = 26), the percentage who were prescribed dose up-titrations to the recommended maintenance DMF dose was 23.1 % at 1-3 months, 26.9 % at 4-6 months, 42.3 % at 7-9 months, and 0 % at 10-12 months. There were no significant differences at any time window among the ODMT groups in the number of office visits or percent of patients receiving MRIs. Mobility indicator patterns (proportion of patients with abnormal gait, wheelchair use, etc.) were consistent over time.


CONCLUSIONS
There was no difference in persistency, prescribing patterns (medication switching, dose reduction, re-starts, and add-ons) or medical resource utilization (office-visits, MRI procedures, and mobility indicators) among the ODMTs. However, in a small sub-group of patients, delays of up to 9 months in DMF dose-up titration to the recommended maintenance dose were observed.
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Tara
T
Nazareth
DataMed Solutions LLC, New York, NY, USA.
Howard S
HS
Friedman
DataMed Solutions LLC, New York, NY, USA.
Prakash
P
Navaratnam
Indegene TTM, Atlanta, GA, USA.
Denise A
DA
Herriott
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA. john.ko@novartis.com.
John J
JJ
Ko
Indegene TTM, Atlanta, GA, USA.
Peri
P
Barr
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Rahul
R
Sasane
Dimethyl fumarate; Disease-modifying therapy; Fingolimod; Medical record; Multiple sclerosis; Oral; Persistency; Prescribing; Resource use; Retrospective; Teriflunomide
J Med Econ. 2014 Oct;17(10):696-707
25019581
J Neurol. 2009 Apr;256(4):568-76
19444532
Mult Scler Relat Disord. 2014 Jul;3(4):513-9
25877064
N Engl J Med. 2012 Sep 20;367(12):1087-97
22992072
N Engl J Med. 2011 Oct 6;365(14):1293-303
21991951
BMC Neurol. 2013 Oct 04;13:138
24093542
N Engl J Med. 2006 Sep 14;355(11):1124-40
16971719
N Engl J Med. 2012 Sep 20;367(12):1098-107
22992073
Mult Scler. 2012 Jul;18(7):932-46
22249762
Clin Ther. 2014 Dec 1;36(12):1946-57
24811754
Lancet. 2008 Oct 25;372(9648):1463-72
18970976
Mayo Clin Proc. 2014 Feb;89(2):225-40
24485135
Patient Prefer Adherence. 2011 Jan 20;5:73-84
21423591